ICU Medical (NASDAQ:ICUI) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why

ICU Medical, Inc. (NASDAQ:ICUI)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $157.00 and traded as high as $162.01. ICU Medical shares last traded at $160.99, with a volume of 133,187 shares trading hands.

Wall Street Analyst Weigh In

ICUI has been the subject of several analyst reports. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Raymond James raised their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, KeyCorp raised their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $199.67.

ICU Medical Price Performance

The company has a 50 day moving average of $163.34 and a 200 day moving average of $157.00. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The firm has a market cap of $3.94 billion, a price-to-earnings ratio of -35.23 and a beta of 0.63.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,973,261.12. This trade represents a 10.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Christian B. Voigtlander sold 1,430 shares of ICU Medical stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $158.00, for a total transaction of $225,940.00. The disclosure for this sale can be found here. Insiders have sold a total of 29,737 shares of company stock valued at $4,941,832 over the last 90 days. 6.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ICUI. Barclays PLC boosted its position in ICU Medical by 15.6% during the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares during the last quarter. LMR Partners LLP bought a new stake in shares of ICU Medical in the third quarter worth $3,884,000. Savant Capital LLC acquired a new position in ICU Medical during the second quarter worth $431,000. Principal Financial Group Inc. grew its position in ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after purchasing an additional 25,031 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in ICU Medical by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock valued at $2,258,000 after buying an additional 6,981 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.